| 2361 |
|
Response: Loss of heterozygosity at the MLL locus/
|
Webb, J
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2362 |
|
Response: morbid complications of hemochromatosis/
|
Ajioka, R. S
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2363 |
|
Response: multiple BCL6 translocation partners in individual cases of gastric lymphoma/
|
Lossos, I. S
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2364 |
|
Response: multiple hypermethylated genes are potential in vivo targets of demethylating agents/
|
Lubbert, M
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2365 |
|
Response: predicting response to ATG for patients with myelodysplastic syndrome/
|
Steensma, D. P
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2366 |
|
Response: pure red cell aplasia and alemtuzumab/
|
Prince, H. M
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2367 |
|
Response: quantitative RT-PCR after NST for CML/
|
Shapira, M. Y
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2368 |
|
Response: renal and other rare late complications following allogeneic stem cell transplantation/
|
Socie, G
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2369 |
|
Response: rituximab and fludarabine combination therapy for CLL: potential future directions of clinical investigation/
|
Byrd, J. C
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2370 |
|
Response: Rituximab in the treatment of acquired factor VIII inhibitors/
|
Wiestner, A
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2371 |
|
Response: Segregation of lipid raft proteins during calcium-induced vesiculation of erythrocytes/
|
Salzer, U
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2372 |
|
Response: source and significance of basic FGF in multiple myeloma/
|
Bisping, G
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2373 |
|
Response: the background level of WT1 expression following allogeneic stem cell transplantation is significantly decreased/
|
Ogawa, H
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2374 |
|
Response: thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): treatment, mortality, and the frequency of HIV infection/
|
Vesely, S. K
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2375 |
|
Response: Transcobalamin 776C>G: significance and determination/
|
Miller, J. W
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2376 |
|
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha/
|
Cortes, J
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2377 |
|
RETRACTION - Retraction of Shan et al. Distinct roles of JNKs/p38 MAP kinase and ERKs in apoptosis and survival of HCD-57 cells induced by withdrawal or addition of erythropoietin. Blood. 2000;94:4067-4076. (Author retraction.)/
|
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|
| 2378 |
|
REVIEW ARTICLE - Antimicrobial proteins and peptides of blood: Templates for novel antimicrobial agents/
|
Levy, O
|
W.B. Saunders Co., etc.]
|
2000
|
|
|
|
| 2379 |
|
REVIEW ARTICLE - Cellular stress response and apoptosis in cancer therapy/
|
Herr, I
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|
| 2380 |
|
REVIEW ARTICLE - Deleterious clinical effects of transfusion-associated immunomodulation: Fact or fiction?/
|
Vamvakas, E C
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|